A lthough local failure after stereotactic radiosurgery (SRS) remains a relatively uncommon phenomenon, with reported rates of local control after 1 year > 90%, the recent improvements in survival seen in patients with brain metastases have made the management of local failures after radiosurgery a relevant clinical issue. 1, 4, 11, 14, 22, 26 Factors associated with local failure that need to be considered when treating these lesions include primary tumor histological type, radiation treatment dose, and intracranial and systemic disease burden. 3, 5, 7, 25 Other ABBREVIATIONS CTCAE = Common Terminology Criteria for Adverse Events; DVH = dose-volume histogram; HR = hazard ratio; IQR = interquartile range; KPS = Karnofsky Performance Scale; OS = overall survival; SRS = stereotactic radiosurgery; WBRT = whole-brain radiation therapy. OBJECTIVE There are a variety of salvage options available for patients with brain metastases who experience local failure after stereotactic radiosurgery (SRS). These options include resection, whole-brain radiation therapy, laser thermoablation, and repeat SRS. There is little data on the safety and efficacy of repeat SRS following local failure of a prior radiosurgical procedure. This study evaluates the clinical outcomes and dosimetric characteristics of patients who experienced tumor recurrence and were subsequently treated with repeat SRS. METHODS Between 2002 and 2015, 32 patients were treated with repeat SRS for local recurrence of ≥ 1 brain metastasis following initial SRS treatment. The Kaplan-Meier method was used to estimate time-to-event outcomes including overall survival (OS), local failure, and radiation necrosis. Cox proportional hazards analysis was performed for predictor variables of interest for each outcome. Composite dose-volume histograms were constructed for each reirradiated lesion, and these were then used to develop a predictive dosimetric model for radiation necrosis. RESULTS Forty-six lesions in 32 patients were re-treated with a second course of SRS after local failure. A median dose of 20 Gy (range 14-22 Gy) was delivered to the tumor margin at the time of repeat SRS. Local control at 1 year was 79% (95% CI 67%-94%). Estimated 1-year OS was 70% (95% CI 55%-88%). Twelve patients had died at the most recent follow-up, with 8/12 patients experiencing neurological death (as described in Patchell et al.). Eleven of 46 (24%) lesions in 11 separate patients treated with repeat SRS were associated with symptomatic radiation necrosis. Freedom from radiation necrosis at 1 year was 71% (95% CI 57%-88%). Analysis of dosimetric data revealed that the volume of a lesion receiving 40 Gy (V 40Gy ) was the most predictive factor for the development of radiation necrosis (p = 0.003). The following V 40Gy thresholds were associated with 10%, 20%, and 50% probabilities of radiation necrosis, respectively: 0.28 cm 3 (95% CI 3%-28%), 0.76 cm 3 (95% CI 9%-39%), 1.60 cm 3 (95% CI 26%-74%). CONCLUSIONS Repeat SRS appears to be an effective salvage option for patients with brain metastases experiencing local failure following initial SRS treatment. This series demonstrates durable local control and, although rates of radiation necrosis are significant, repeat SRS may be indicated for select cases of local disease recurrence. Because the V 40Gy is predictive of radiation necrosis, limiting this value during treatment planning may allow for a reduction in radiation necrosis rates.
important factors to consider are the life expectancy of the patient and the possibility that imaging changes that appear consistent with treatment failure could at times represent radiation necrosis. Differentiating between radiation necrosis and tumor recurrence is an important consideration. Although the only definitive method of confirming recurrence is tissue biopsy, careful protocols of surveillance with perfusion-weighted MRI can distinguish between recurrence and necrosis, 20 thus helping mitigate the risks associated with re-treatment.
Resection is used at some institutions as the salvage therapy of choice for patients who experience local treatment failure after SRS because it gives providers the ability to confirm progression by evaluating pathological specimens and has the potential to quickly palliate any symptoms present if the lesion is in a favorable location with regard to accessibility and proximity to eloquent brain structures. One drawback of surgery, however, is that it often requires further adjuvant therapy to decrease the risk of local failure. 16, 17 Another localized treatment option is laser thermoablation, an approach that has recently been used for surgically inaccessible lesions. 19 In cases wherein treatment failure is more diffuse or there is evidence of leptomeningeal failure, whole-brain radiation therapy (WBRT) is commonly used. 9 However, because WBRT increases the risk of acute worsening of performance status and chronic cognitive decline, its use for isolated local failure or for local failure with only limited distant brain metastases is often not ideal. 6 In select patients who have experienced local treatment failure after SRS and in whom neither surgery nor WBRT is optimal, repeat SRS is often performed; however there is little data on the safety and efficacy of this technique. The concern with repeat SRS is the theoretically high risk of radiation necrosis, given the high cumulative dose and extreme hypofractionation of radiation delivered to the same volume. The current study represents the largest series with the longest follow-up in which outcomes are reported for patients receiving SRS as re-treatment following local failure after initial SRS. This study evaluates the clinical outcomes of repeat Gamma Knife (Elekta AB) SRS, including local control, overall survival (OS), and likelihood of neurological death, as well as factors predictive of radiation necrosis.
Methods

Data Acquisition
This is a single-institution retrospective review that was approved by our institutional review board. The Radiation Oncology Gamma Knife database at our institution was queried for all patients who received radiosurgical treatment more than once. The GammaPlan Treatment Planning System (Elekta AB) was subsequently used to identify lesions that were treated a second time after local failure of the initial radiosurgery. Local failure was defined either as a histologically proven recurrence or as serial increases in the size of an enhancing mass on axial slice MRI with corresponding increased perfusion on perfusion-weighted MRI. For small recurrences below the sensitivity of perfusion (< 1 cm 3 ), tumors were followed with serial MRI, and a volumetric increase of ≥ 200% was required to determine local failure significant enough to warrant repeat SRS. Patients were selected for repeat SRS if they had either an unresectable local recurrence or multifocal (concurrent local and distant) recurrences that could be addressed in the same treatment session. Patients with small local recurrences were considered for this technique if they met the above criteria or if they had either worsening performance status or refused surgical treatment. Electronic medical records were reviewed to determine patient characteristics including age, sex, histological findings, extracranial disease status, Karnofsky Performance Scale (KPS) score, prior WBRT, and prior surgery. Outcomes including local control, toxicity, and radiation necrosis were also determined via the electronic medical records.
Radiosurgery Technique
Prior to SRS, each patient underwent high-resolution contrast-enhanced MRI studies of the brain. Treatment planning was performed using the GammaPlan system. The SRS was performed using either the Leksell Model (Elekta AB) . Prescriptions for initial SRS treatments were determined based on guidelines published by Shaw et al. 21 Doses chosen for the repeat SRS treatment were determined by physician discretion, but were generally also based on these guidelines. At the time of repeat SRS, doses were commonly chosen at the lower end of the dose range for an appropriate volume, particularly in those patients who had also received previous WBRT. In all patients in this series the SRS was delivered in a single fraction.
Response Assessment
Patients were followed with serial MRI after each SRS procedure. Posttreatment MRI was performed 6-8 weeks following SRS and subsequently every 3 months thereafter. Local failure was defined as either a histologically proven recurrence or serial increases in the size of the area of enhancement with corresponding increased perfusion on perfusion-weighted MRI. As stated above, small recurrences were followed with serial MRI, and a volumetric increase of ≥ 200% was required to determine local failure significant enough to warrant repeat SRS. For lesions > 1 cm 3 , local progression was determined by either biopsy confirmation or a 25% increase in the area of enhancement on axial slice MRI, with a corresponding increase in perfusion on perfusion-weighted MRI. For cases in which it was initially difficult to differentiate local failure from radiation necrosis or the development of granulation tissue, patients were treated conservatively with dexamethasone until recurrence was determined as detailed above. Cases were deemed radiation necrosis after either pathological confirmation or when serial imaging and conservative treatment with steroids ultimately led to stabilized imaging findings. The prescribed regimen of dexamethasone was 4 mg twice daily for 1 week, followed by a taper of 2 mg per week thereafter until the patient was taken off the medication.
Local failures were classified as either central or marginal failures. Central failures were defined as occurring within the prescribed treatment margin, whereas marginal failures were defined as occurring outside of the prescribed treatment margin. Figure 1 shows representative imaging for a patient treated with repeat SRS after a central failure. Neurological death was defined as previously reported by Patchell et al. 17 Imaging results were also correlated with observed clinical deterioration as defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. Patients diagnosed with radiation necrosis were treated conservatively with dexamethasone (duration and dose as detailed above) and the combination of vitamin E and pentoxifylline. In cases of severe radiation necrosis, patients underwent resection to palliate symptomatic deterioration.
Statistical Analysis
Follow-up time and time-to-event outcomes were calculated from the time of SRS re-treatment to the time of most recent follow-up or to the event of interest. Timeto-event end points included time to local failure, time to death (i.e., OS), and time to development of radiation necrosis. All time-to-event data were summarized using the Kaplan-Meier estimator. Univariate Cox proportional hazards analysis was performed for each predictor variable and for all time-to-event outcomes.
Dosimetric Analysis
For each SRS treatment, relevant Digital Imaging and Communications in Medicine-Radiation Therapy (DICOM-RT) files were exported from GammaPlan and reconstructed using MIM Maestro v6.4 (MIM Software). Radiation therapy doses were then calculated using the Tissue Maximum Ratio 10-dose algorithm and composite plans were then formed, which allowed for the creation of an absolute cumulative dose-volume histogram (DVH) for each treated lesion. Absolute dose, rather than biologically equivalent dose, was used to maximize clinical applicability. Dose-volume relationships were analyzed at intervals of 0.1 Gy from total doses of 0-100 Gy. Serial logistic regression analyses were performed for each discrete dose (at 0.1-Gy intervals) received by a certain volume. A fitted logistic regression model was developed after selecting a discrete dose that was statistically predictive of radiation necrosis as well as clinically applicable.
Results
Patient Population
Between 2002 and 2015, 738 patients received upfront SRS for brain metastases, with 58 experiencing local failure. Of these 58 patients experiencing local failure, 32 were treated with a second course of Gamma Knife SRS to a total of 46 discrete lesions. Local failure in this cohort was confirmed by biopsy in 11 patients (34%); in the remainder failure was determined by serial increases in size on axial MRI in accordance with the aforementioned response criteria. The median patient age was 59 years (range 36-88 years). The median time to repeat SRS was 19 months (range 2-98 months). The median tumor volume at first Six patients (19%) had multiple lesions treated with repeat SRS. The most common primary tumors originated in the lung, with 10 (31%) identified as adenocarcinoma, 6 (19%) as squamous cell carcinoma, and 1 (3%) as small cell carcinoma. Nine (28%) primary tumors were of breast origin, with 3 (9%) were identified as Her2/Neu-positive adenocarcinoma. Two (6%) patients presented with renal cell carcinoma and another 2 (6%) with metastatic melanoma. A single patient (3%) was treated for a brain metastasis from esthesioneuroblastoma. Twenty-one (66%) patients had stable extracranial disease at the time of repeat SRS, with the remaining 11 (34%) showing evidence of progressive disease. The median KPS score was 80 (range 60-100). The median dose delivered to the tumor margin at the time of first SRS was 20 Gy (range 12-24 Gy). The median dose delivered to the tumor margin at the time of repeat SRS was 20 Gy (range 14-22 Gy). Figure 2 plots the radiation doses chosen for each patient at initial and repeat SRS. The SRS was delivered in a single fraction to each lesion. Table  1 summarizes the patient characteristics in this study. 
Overall Survival
The median length of follow-up after repeat SRS was 24 months (range 2-124 months). The OS at 1 year following re-treatment was 70% (95% CI 55%-88%). The median OS had not yet been reached at the time of analysis. The Kaplan-Meier plot for OS is shown in Fig. 3A .
Cox univariate analysis revealed a statistically significant relationship between the lowest treatment dose per patient at the time of the second SRS and OS (hazard ratio [HR] 0.64, p = 0.001). Table 2 depicts Cox univariate analysis for factors affecting OS by patient. The most common cause of mortality was neurological death (67%).
Patterns of Failure
One-year local control for each lesion was 79% (95% CI 67%-94%). Figure 3B depicts a Kaplan-Meier plot for freedom from local failure. The median time to local failure after the second SRS was 95.6 months, with only 9 events reported. Of those 9, 5 (56%) occurred outside the margins of the treatment area and 4 (44%) occurred within the margins of the treatment area.
Radiation Necrosis and Adverse Events
In 14 of 46 cases (30%) the patient experienced radiation necrosis, with 11 of 46 (24%) showing evidence of symptomatic decline. In 3 (9%) patients radiation necrosis was confirmed by biopsy, with the remainder confirmed by imaging. Five patients (16%) experienced unsteadiness and dyscoordination as a result of cerebellar radiation necrosis; all of them showed improvement over time with corticosteroid treatment and rehabilitation. Three patients (9%) experienced motor weakness of the hand and face; 2 of them showed some improvement with therapy. Two patients (6%) experienced visual field changes; one had some improvement, although with residual blurriness, whereas the other still has a complete homonymous hemianopia after resection of significant radiation necrosis. One patient experienced transient word-finding difficulty, and another experienced expressive aphasia and continues to have some residual difficulty. A single patient had hemorrhage at the re-treatment site, which required surgical intervention. Aside from toxicity from radiation necrosis, 4 patients (13%) experienced Grade 1 toxicity according to the Radiation Therapy Oncology Group grading system; there were no other serious adverse events. After re-treatment, the 1-year freedom from radiation necrosis was 71% (95% CI 57%-88%). The median time from repeat SRS to the development of radiation necrosis for the entire cohort was 44.4 months by Kaplan-Meier estimation. For those lesions in which radiation necrosis actually developed, the mean time to this event was 8.0 months (interquartile range [IQR] 3.8-19.7 months). The median time to radiation necrosis after initial SRS as estimated by the Kaplan-Meier method was 91.1 months. The median time to necrosis for tumors that actually developed radiation necrosis after the first SRS was 28.4 months (IQR 21.0-54.7). Figure 3C depicts a Kaplan-Meier plot for freedom from radiation necrosis. The volume of recurrent tumor at the time of repeat SRS was predictive of radiation necrosis on univariate analysis (HR 1.19, p = 0.002). Of 46 lesions treated, 38 had the necessary dosimetric data for inclusion in dosimetric analysis. For these lesions, cumulative DVH data were analyzed and serial logistic regression analyses were performed at 0.1-Gy intervals, the results of which revealed the cumulative dose delivered to a volume of tissue (V D ) for doses between 22 Gy and 63 Gy to be statistically significant predictors of the development of radiation necrosis. The most statistically significant relationship between the V D and radiation necrosis was at V 40.8Gy (p = 0.003) (Fig. 4) . To maximize clinical applicability, V 40Gy was used to develop the fitted logistic regression model (Fig. 5) . The following V 40Gy thresholds were associated with 10%, 20%, and 50% probabilities of radiation necrosis, respectively: 0.28 cm 3 (95% CI 3%-28%), 0.76 cm 3 (95% CI 9%-39%), 1.60 cm 3 (95% CI 26%-74%).
Further Salvage
Of the 8 patients (with a total of 9 lesions) who experienced local failure after repeat SRS, 3 went on to receive WBRT, 3 underwent resection, a single patient underwent laser thermoablation, and 1 patient opted for no further therapy and was placed in hospice care. Three patients experiencing local failure were dead at the time of data analysis, with 2 of these deaths being attributable to neurological causes.
Discussion
In the current study we investigated repeat SRS for brain metastases in patients who have experienced local treatment failure. This series demonstrates durable local control, successful salvage outcomes, and a possible dosimetric threshold for predicting radiation necrosis. Several salvage approaches currently exist for addressing local failure after radiosurgery, and the clinical scenario may ultimately predict which approach is optimal. Repeat SRS may be a reasonable option for cases wherein patients experience simultaneous local and distant brain recurrences, because SRS can be applied to treat both progressive and new brain metastases in the same treatment session while minimizing the total radiation exposure of surrounding tissue. Repeat SRS may also be helpful for lesions that are located in surgically inaccessible regions. Repeat SRS is probably a suboptimal approach in the treatment of larger lesions or in lesions that have experienced rapid local failure, due to the high risk of suboptimal local control or the development of radiation necrosis in those situations.
Several patients in the current series lived multiple years after repeat SRS for treatment of a local failure. This finding highlights the survivability following local failure if properly treated. Several recent analyses have been performed assessing the causes of death in patients with brain metastases. Whereas most patients with brain metastases ultimately die of systemic disease, those that have controlled extracranial disease are more likely to die of brain metastases. 13 Patients with well-controlled extracranial disease are also more likely to experience local failures intracranially. This would explain the high rate of neurological death (67%) for patients who died in the current series. Durable salvage options for intracranial disease are thus quite important for patients who experience local failure after initial treatment with SRS.
In the present literature, there exist only a few series reporting outcomes following repeat radiosurgery for local failure in brain metastases. Jayachandran et al. showed a higher radiation necrosis rate in lesions treated with repeat SRS following local failure as compared with either a single application of SRS or SRS after failure of conventionally fractionated radiotherapy. 10 Bhatnagar et al. reported good treatment response in both local and distant brain recurrences with repeat SRS. They also noted an association between increased re-treatment volume and the probability of neurological decline. 2 Holt et al. reported acceptable rates of toxicity in patients treated with repeat SRS following resection of a prior SRS. Resection of the previously treated lesion may have influenced the toxicity rates by decreasing the volume of re-treated tumor. 8 In our series and in those mentioned above, radiosurgery was delivered in a single fraction for each patient. A recent report by McTyre et al., however, describes good outcomes in 3 patients with brain metastases treated with hypofractionated SRS after having failed single-fraction radiosurgery; this strategy was chosen for large lesions deemed to be at higher risk for radiation necrosis. 15 Given that hypofractionation is thought to decrease the risk of radiation necrosis, their findings represent an intriguing clinical option for patients with local recurrence after a prior SRS treatment.
In the present series, approximately 24% of re-treated lesions were associated with symptomatic radiation necrosis. Three patients (9%) who experienced necrosis had a CTCAE Grade 3 or higher toxicity. Five patients were left with residual deficits after the development of radiation necrosis, the severity of which was dependent on the grade of toxicity and the proximity of the lesion to eloquent brain. No patients died of toxicity. A single patient in the present series had a lesion that was re-treated within the brainstem. This particular patient was not deemed a surgical candidate, experienced improvement of a facial nerve palsy after repeat SRS, and lived for another 7 months without evidence of radiation necrosis. Although these results are encouraging, there is certainly a need for additional reported cases before re-treatment of lesions within the brainstem can be considered safe, because prior series have demonstrated higher rates of toxicity with SRS in this location. 12 Volumetric analysis from the present series was able to determine that the volume that received a cumulative dose of 40 Gy over 2 SRS treatments was predictive of the development of radiation necrosis. This threshold represents a significant advance; the practice of repeating SRS after previously treated SRS failures has been communicated anecdotally at some centers and is scantily reported, with no previous evidence for dose or volume constraints. It is thought that the mechanism of damage to tumors as well as normal tissues with extreme hypofractionation is different than with conventionally fractionated radiation because the vasculature is affected more with hypofractionation. 24 Several investigators have reported the use of repeat SRS for arteriovenous malformations in which there were acceptable rates of radiation necrosis. 18, 23 The use of this dosimetric data in the future will probably be 2-fold. First, it may assist in determining which patients are candidates for safe administration of repeat SRS treatments. Second, it may guide the process of determining the dose prescribed at re-treatment. Patients with lesions predicted to receive a cumulative V 40Gy < 0.3 cm 3 after repeat SRS have a 10% probability of radiation necrosis and are probably safe to re-treat with SRS. For lesions with a predicted V 40Gy > 1.6 cm 3 (50% likelihood of radiation necrosis), lowering the treatment dose or finding an alternative treatment modality would be advisable.
There are several limitations to the current series. As a retrospective series, its findings are generally limited to hypothesis generation. The potential use of the V 40Gy as a dosimetric constraint to consider in re-treatment scenarios is intriguing, although further evaluation of the V 40Gy and other potential dosimetric parameters as possible predictors of radiation necrosis is warranted. This is particularly true given the small sample size and number of radiation necrosis events in this series. Furthermore, all patients in this series received Gamma Knife SRS, so despite the theoretical generalizability of Gamma Knife SRS dosimetric constraints to LINAC-based SRS, this deserves further investigation. Despite these limitations, and in the absence of other constraints from which to guide the re-treatment of brain metastases with SRS, minimizing the V 40Gy may be a useful strategy for clinicians who wish to decrease the probability of radiation necrosis and its associated toxicities.
Conclusions
Repeat Gamma Knife SRS appears to be an effective salvage option for brain metastases initially treated with SRS. This series demonstrates durable local control and successful salvage outcomes. Although this strategy does carry a relatively high risk for radiation necrosis, it may be indicated for select cases of disease recurrence. Furthermore, the risk for radiation necrosis may be minimized with careful patient selection and treatment planning. The volume receiving 40 Gy is the most significant predictor of the development of radiation necrosis; therefore it may be a useful consideration during the SRS planning process as a means of minimizing the risk to these patients. 
